Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.
We have designed a membrane-anchored form of the Toll-like receptor 5 ligand flagellin, the major proinflammatory determinant of enteropathogenic Salmonella, which was found to be glycosylated and expressed on cell surfaces. A chimeric influenza virus-like particle (cVLP) vaccine candidate containing A/PR8/34 (H(1)N(1)) hemagglutinin (HA), matrix protein (M1), and the modified flagellin as a molecular adjuvant was produced. The immunogenicity, including the serum antibody levels and cellular immune responses, and the protective efficacy against homologous and heterologous live virus challenge of the resulting VLPs were tested after intramuscular administration in a mouse model. The results demonstrated that flagellin-containing VLPs elicited higher specific immunoglobulin G (IgG) responses than standard HA and M1 VLPs, indicating the adjuvant effect of flagellin. Enhanced IgG2a and IgG2b but not IgG1 responses were observed with flagellin-containing VLPs, illuminating the activation of Th1 class immunity. The adjuvant effects of flagellin were also reflected by enhanced specific cellular responses revealed by the secretion of cytokines by freshly isolated splenocyte cultures when stimulated with pools of major histocompatibility complex class I or II peptides. When immunized mice were challenged with homologous live PR8 virus, complete protection was observed for both the standard and cVLP groups. However, when a heterosubtypic A/Philippines (H(3)N(2)) virus was used for challenge, all of the standard VLP group lost at least 25% of body weight, reaching the experimental endpoint. In contrast, for the cVLP group, 67% of mice survived the challenge infection. These results reveal that cVLPs designed by incorporating flagellin as a membrane-anchored adjuvant induce enhanced cross-protective heterosubtypic immune responses. They also indicate that such cVLP vaccines are a promising new approach for protection against pandemic influenza viruses.
Wang
Bao-Zhong
BZ
Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Atlanta, Georgia 30322, USA.
Quan
Fu-Shi
FS
Kang
Sang-Moo
SM
Bozja
Jadranka
J
Skountzou
Ioanna
I
Compans
Richard W
RW
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002460:Cell Line; D005260:Female; D005408:Flagellin / Q000235:genetics / Q000276:immunology*; D006031:Glycosylation; D006385:Hemagglutination Inhibition Tests; D007114:Immunization; D007252:Influenza Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018411:Spodoptera; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051198:Toll-Like Receptor 5 / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D014771:Virion / Q000276:immunology*
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D051198:Toll-Like Receptor 5; D014409:Tumor Necrosis Factor-alpha; D005408:Flagellin
Nature. 2000 Dec 7;408(6813):740-5
11130078
J Infect Dis. 2007 Jun 1;195(11):1607-17
17471430
J Immunol. 2001 May 1;166(9):5688-94
11313410
Int Rev Immunol. 1989;5(2):165-71
8691049
Vaccine. 2007 May 10;25(19):3871-8
17337102
J Virol. 2007 Feb;81(3):1319-26
17121795
Nat Med. 2004 Dec;10(12 Suppl):S82-7
15577936
J Immunol. 2003 May 15;170(10):5165-75
12734364
Science. 2004 Mar 5;303(5663):1522-6
15001781
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12162-7
11593031
Front Biosci. 2008 May 01;13:5094-107
18508572
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10805-10
11535838
Infect Immun. 2004 May;72(5):2810-6
15102791
J Exp Med. 1999 Jan 18;189(2):371-80
9892619
Emerg Infect Dis. 2006 Jan;12(1):61-5
16494719
Infect Immun. 1999 Oct;67(10):5176-85
10496893
J Gen Virol. 1976 Oct;33(1):159-63
978183
Virology. 1996 Jul 1;221(1):87-97
8661417
Viral Immunol. 2007 Sep;20(3):441-52
17931114
Nat Rev Immunol. 2007 Apr;7(4):267-78
17363960
Viral Immunol. 2005;18(1):244-51
15802970
Nature. 2005 Oct 6;437(7060):889-93
16208372
Vaccine. 2008 Jan 10;26(2):201-14
18063235
Infect Immun. 1998 Mar;66(3):1127-34
9488405
Antiviral Res. 2007 Oct;76(1):75-85
17617476
J Exp Med. 1998 Apr 20;187(8):1193-204
9547331
J Leukoc Biol. 2005 Oct;78(4):888-97
16033815
Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7181-6
17435166
J Exp Med. 2003 Nov 17;198(10):1563-72
14623910
J Virol. 1974 Nov;14(5):1307-9
4372400
Eur J Immunol. 2000 Dec;30(12):3591-7
11169401
Lancet. 1990 Jan 20;335(8682):179-80
1967480
Infect Immun. 2001 Jul;69(7):4424-9
11401982
J Virol. 2007 Feb;81(3):1083-94
17108046
J Clin Invest. 1989 Feb;83(2):355-61
2643627
Vaccine. 2000 May 22;18(23):2592-9
10775793
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9814-9
9275208
J Immunol. 2002 Oct 1;169(7):3914-9
12244190
J Virol. 2000 Sep;74(18):8709-19
10954572
J Virol. 2007 Apr;81(7):3514-24
17251294
Med Microbiol Immunol. 2007 Dec;196(4):213-25
17541633
Vaccine. 2005 Dec 30;23(50):5751-9
16143432
J Immunol. 2003 Jun 15;170(12):6217-23
12794153
J Virol. 1999 Jun;73(6):5098-109
10233973
J Virol. 2003 Sep;77(18):9823-30
12941891
Nat Immunol. 2003 Dec;4(12):1247-53
14625549
Infect Immun. 2004 Nov;72(11):6676-9
15501801
N Engl J Med. 2002 Nov 21;347(21):1645-51
12444178
Anal Biochem. 1989 Aug 1;180(2):195-204
2510544
Vaccine. 2003 May 1;21(16):1789-95
12686096
J Virol. 2008 Feb;82(3):1350-9
18032492
J Virol. 2007 Oct;81(20):10869-78
17670815
Immunol Lett. 1998 Nov;64(1):9-15
9865596
Infect Immun. 2006 Feb;74(2):1113-20
16428759
Curr Opin Immunol. 1989 Oct;2(1):63-7
2532914
Eur J Immunol. 2004 Nov;34(11):2986-95
15384042
Microbiology (Reading). 2006 May;152(Pt 5):1249-1262
16622043
J Exp Med. 1997 Feb 3;185(3):551-62
9053455
Immunity. 1999 Oct;11(4):443-51
10549626
J Immunol. 2004 Jun 1;172(11):6922-30
15153511
Scand J Immunol. 2007 Apr;65(4):320-8
17386022
Curr Top Microbiol Immunol. 2002;270:93-108
12467246
Eur J Immunol. 2004 May;34(5):1483-7
15114682
Virology. 2006 Aug 1;351(2):303-11
16690097
J Bacteriol. 2004 May;186(9):2523-31
15090491
Adv Virus Res. 2006;68:159-91
16997012